Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Shape Therapeutics, Roche Form $3B RNA Editing Collaboration
11:41am, Tuesday, 24'th Aug 2021
Shape Therapeutics Inc announced a multi-target strategic collaboration and license agreement with Roche Holding AG (OTC: RHHBY) for RNA editing technology. Through this partnership, ShapeTX wil
Cathie Wood's ARK Invest Sells Over 175,000 Shares of Roche
09:48am, Friday, 20'th Aug 2021
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 175,000 shares of Roche Holding AG (NYSEARCA: RHHBY) on Thursday, as the share price of this fund traded down nearly 2% in the
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
09:47am, Friday, 20'th Aug 2021
The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent and treat COVID-19. The U.K. chief m
Analog Devices, Inc. (ADI) CEO Vince Roche on Q3 2021 Results - Earnings Call Transcript
01:05pm, Wednesday, 18'th Aug 2021
Analog Devices, Inc. (ADI) CEO Vince Roche on Q3 2021 Results - Earnings Call Transcript
Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
11:35am, Wednesday, 18'th Aug 2021
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to perso
Roche says arthritis drug authorized to treat hospitalized COVID-19 patients is in short supply
03:01pm, Tuesday, 17'th Aug 2021
Roche Holding AG ROG, +0.45% said Monday that Actemra, its rheumatoid arthritis drug that recently received authorization in the U.S. as a COVID-19 treatment for hospitalized patients, is in short sup
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage
07:47am, Tuesday, 17'th Aug 2021
Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after showing it cut the risk of death. Less tha
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
04:06pm, Monday, 09'th Aug 2021
AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu. The trial reached its prima
Valuations Matter: 5 Bargains In A Sea Of Overvalued Monsters
07:13am, Monday, 09'th Aug 2021
Valuations Matter: 5 Bargains In A Sea Of Overvalued Monsters
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the pivotal Phase III POLARIX trial investigating Polivy® (pola
Here Are the Winners of Cowen's Big Pharma R&D Showdown
10:02am, Saturday, 07'th Aug 2021
The Wall Street firm put big drugmakers' R&D programs through five different tests.
This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money
09:39am, Wednesday, 04'th Aug 2021
An effective oral antiviral therapy for the coronavirus may be around the corner.
SoftBank Said to Build $5 Billion Stake in Roche
09:06pm, Tuesday, 03'rd Aug 2021
Aug.03 -- Bloomberg has learned that SoftBank Group Corp. has built a $5 billion stake in Roche Holding AG, placing a big bet on the pharma giant's strategy of using data to develop drugs. We've also
Roche's Tecentriq As Adjuvant Treatment Under Priority Review With FDA For Early Lung Cancer
06:32am, Tuesday, 03'rd Aug 2021
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) Tecentriq (atezolizumab), as adjuvant treatment for certain patients with early non-small cell lung c
US FDA grants Priority Review to Roche's Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
01:00am, Tuesday, 03'rd Aug 2021
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) an
